Abstract
Ad-PPE-Fas-c is an adenovector that expresses Fas-c under the control of the modified pre-proendothelin-1 (PPE-1) promoter. Fas-c is a chimeric death receptor containing the extracellular portion of tumour necrosis factor 1 receptor (TNFR1) and the transmembrane and intracellular portion of Fas. We recently demonstrated that Ad-PPE-Fas-c induced Fas-receptor-mediated endothelial cell apoptosis. Previously, doxorubicin was shown to enhance Fas-receptor clustering and the induction of its cascade. Therefore, the goal of this work was to test whether doxorubicin augments the capacity of Ad-PPE-Fas-c to induce endothelial cell apoptosis and to elucidate whether either the death-receptor-mediated apoptotic cascade or the mitochondria-associated apoptotic cascade is involved in the combined treatment effect. We found that a combined treatment of Ad-PPE-Fas-c and doxorubicin synergistically induced a reduction in endothelial cell viability and apoptosis. z-IETD-FMK, a caspase-8 inhibitor, and z-LEHD-FMK, a caspase-9 inhibitor, significantly decreased apoptosis induced by the combined treatment. Systemically administered combined therapy significantly reduced the lung metastases burden (70%) in mice as compared to each treatment alone. Thus, a combined treatment of Ad-PPE-Fas-c gene therapy and chemotherapy may be effective in the treatment of metastatic diseases and both the Fas cascade and the mitochondria-associated cascade are essential for this effect.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sivridis E, Giatromanolaki A, Koukourakis MI . The vascular network of tumours—what is it not for? J Pathol 2003; 201: 173–180.
Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D . A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995; 270: 7795–7798.
Chinnaiyan AM, O’Rourke K, Tewari M, Dixit VM . FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505–512.
Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995; 14: 5579–5588.
Muzio M, Chinnaiyan AM, Kischkel FC, O′Rourke K, Shevchenko A, Ni J et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death—inducing signaling complex. Cell 1996; 85: 817–827.
Laurent G, Jaffrezou JP . Signaling pathways activated by daunorubicin. Blood 2001; 98: 913–924.
Khatib AM, Kontogiannea M, Fallavollita L, Jamison B, Meterissian S, Brodt P . Rapid induction of cytokine and E-selectin expression in the liver in response to metastatic tumor cells. Cancer Res 1999; 59: 1356–1361.
Wang X . The expanding role of mitochondria in apoptosis. Genes Dev 2001; 15: 2922–2933.
Stennicke HR, Jurgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X et al. Pro-caspase-3 is a major physiologic target of caspase-8. J Biol Chem 1998; 273: 27084–27090.
Greenberger S, Shaish A, Varda-Bloom N, Levanon K, Breitbart E, Goldberg I et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest 2004; 113: 1017–1024.
Varda-Bloom N, Shaish A, Gonen A, Levanon K, Greenbereger S, Ferber S et al. Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther 2001; 8: 819–827.
Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT . Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem 1999; 274: 7987–7992.
Lin T, Zhang L, Davis J, Gu J, Nishizaki M, Ji L et al. Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 2003; 8: 441–448.
Quesada AJ, Nelius T, Yap R, Zaichuk TA, Alfranca A, Filleur S et al. In vivo upregulation of CD95 and CD95 L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment. Cell Death Differ 2005; 12: 649–658.
Chou TC, Talalay P . Generalized equations for the analysis of inhibitions of Michaelis–Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981; 115: 207–216.
Chou TC, Talalay P . Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.
Stripecke R, Carmen Villacres M, Skelton D, Satake N, Halene S, Kohn D . Immune response to green fluorescent protein: implications for gene therapy. Gene Ther 1999; 6: 1305–1312.
Sawyer DB, Fukazawa R, Arstall MA, Kelly RA . Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res 1999; 84: 257–265.
Kalyanaraman B, Perez-Reyes E, Mason RP . Spin-trapping and direct electron spin resonance investigations of the redox metabolism of quinone anticancer drugs. Biochim Biophys Acta 1980; 630: 119–130.
Kotamraju S, Konorev EA, Joseph J, Kalyanaraman B . Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. J Biol Chem 2000; 275: 33585–33592.
Wang L, Ma W, Markovich R, Chen JW, Wang PH . Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 1998; 83: 516–522.
Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H, Koh E . Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 2000; 102: 572–578.
Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M . FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol 1998; 161: 3936–3942.
Lorenzo E, Ruiz-Ruiz C, Quesada AJ, Hernandez G, Rodriguez A, Lopez-Rivas A et al. Doxorubicin induces apoptosis and CD95 gene expression in human primary endothelial cells through a p53-dependent mechanism. J Biol Chem 2002; 277: 10883–10892.
Cory S, Adams JM . The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647–656.
Cowling V, Downward J . Caspase-6 is the direct activator of caspase-8 in the cytochrome c-induced apoptosis pathway: absolute requirement for removal of caspase-6 prodomain. Cell Death Differ 2002; 9: 1046–1056.
Kuo CJ, Farnebo F, Yu EY, Christofferson R, Swearingen RA, Carter R et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001; 98: 4605–4610.
Boehm T, Folkman J, Browder T, O′Reilly MS . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407.
O’Reilly MS, Holmgren L, Chen C, Folkman J . Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689–692.
Denekamp J . Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66: 181–196.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Peled, M., Shaish, A., Greenberger, S. et al. Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect. Cancer Gene Ther 15, 535–542 (2008). https://doi.org/10.1038/cgt.2008.20
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2008.20